TITLE

2010 - PPI use in the first trimester was not associated with increased risk for birth defects; PPI use 1 to 4 weeks before conception was

AUTHOR(S)
Windrim, Rory
PUB. DATE
June 2011
SOURCE
ACP Journal Club;6/21/2011, Vol. 154 Issue 6, p10
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports on a study conducted by Pasternak B. and Hviid A. focusing on the association between use of proton-pump inhibitors (PPIs) in early pregnancy and the risk of birth defects. The study showed that infants born to women who used PPIs during the first trimester or second and third trimesters did not have an increased risk for major birth defects. It concluded that the use of PPIs 1 to 4 weeks before conception was associated with the risk for major birth defects.
ACCESSION #
65457002

 

Related Articles

  • 2010 - PPI use in the first trimester was not associated with increased risk for birth defects; PPI use 1 to 4 weeks before conception was. Windrim, Rory // ACP Journal Club;6/21/2011, Vol. 154 Issue 6, p10 

    Question Is exposure to proton-pump inhibitors (PPIs) in early pregnancy associated with risk for major birth defects? Methods Design Cohort study with linkage of national birth, prescription, and patient registers. Setting Denmark. Participants 840>968 infants born alive between 1996 and 30...

  • Use of Proton-Pump Inhibitors in Early Pregnancy and the Risk of Birth Defects. Pasternak, Bj�rn; Hviid, Anders // New England Journal of Medicine;11/25/2010, Vol. 363 Issue 22, p2114 

    Background: Symptoms of gastroesophageal reflux are common in pregnancy, but there are limited data on the risk of birth defects associated with exposure to proton-pump inhibitors (PPIs) in early pregnancy. Methods: We conducted a cohort study to assess the association between exposure to PPIs...

  • Study finds PPI pneumonia link.  // Pulse;5/24/2007, Vol. 67 Issue 20, p12 

    The article focuses on the risk of proton pump inhibitors (PPI) to patients with pneumonia in Great Britain. Study shows that PPI raise pneumonia risk five-fold in the first week after its initiation. It was found out that the use of PPI increased the risk by 50 percent. The risk rose to 400...

  • No black and white answer to SSRI teratogenicity question.  // Reactions Weekly;7/7/2007, Issue 1159, p5 

    This article focuses on a study which examined the association between first-trimester use of selective serotonin reuptake inhibitors (SSRI) and birth defects. An overview of the study population is presented, as well as a description of the methodology. Results revealed that maternal use of...

  • Maternal opioid use raises congenital heart defect risk.  // Contemporary OB/GYN;Sep2011, Vol. 56 Issue 9, p20 

    The National Birth Defects Prevention Study is discussed, which revealed that the use of opioid analgesics by women just before, or in the first trimester of pregnancy, increases the risk for congenital heart defects among their children.

  • Risk of some birth defects increased with opioid exposure.  // Reactions Weekly;3/12/2011, Issue 1342, p4 

    The article discusses the findings of researchers from the U.S. and Canada that infants born to women using opioid analgesics in the month before pregnancy or in the first trimester face an increased risk of certain birth defects.

  • Fluconazole use during the first trimester of pregnancy was not associated with most major birth defects. Magee, Laura A. // ACP Journal Club;1/21/2014, Vol. 160 Issue 2, p1 

    The article focuses on a study regarding the use of oral azole antifungal agent fluconazole during the first trimester of pregnancy in increasing increase risk for major birth defects in offspring. Topics discussed include the study revealing that the use of fluconazole during the first...

  • No increased risk of birth defects with fluconazole.  // Reactions Weekly;9/7/2013, Issue 1468, p1 

    The article reports on a study which evaluates the association between the use of fluconazole during the first-trimester of pregnancy and the risk of major birth defects.

  • Co-prescribing of proton pump inhibitors among chronic users of NSAIDs in the UK. D.-C. Suh; E. Hunsche; H.-C. Shin; P. Mavros // Rheumatology;Apr2008, Vol. 47 Issue 4, p458 

    Objectives. Co-prescribing of proton pump inhibitors (PPIs) with non-selective NSAIDs (nsNSAIDs) is recommended in patients at risk of gastrointestinal (GI) events. This study estimated usage of PPI co-therapy among chronic nsNSAID users and determined factors associated with concurrent...

Share

Read the Article

Courtesy of AIRBUS FRANCE S.A.S.

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics